Substance use & misuse · 2010
Validity of self-reported misuse of prescription opioid analgesics.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smith Meredith, Rosenblum Andrew, Parrino Mark, Fong Chunki, Colucci Salvatore
Аннотация
AIM: To determine concurrent validity of self-reported misuse of prescription opioids.
DESIGN AND SETTING: Cross-sectional study in five U.S. methadone maintenance programs.
PARTICIPANTS: 92 addicts.
MEASUREMENTS: Self-reported questionnaire assessing past-month misuse of 14 opioid analgesics, and color photographs of five opioid analgesics with instructions to mark those used in the past month "to get high." Concordance between self-report and photograph endorsement was assessed via Kappa statistic.
FINDINGS: 29 respondents completed both questionnaire and photograph endorsements. Kappas were 0.62 (OxyContin), 0.59 (methadone), 0.49 (Dilaudid), and 0.46 (generic extended-release oxycodone).
CONCLUSIONS: Good-to-fair concurrent validity of self-reported abuse was seen for OxyContin, methadone, Dilaudid, and generic extended-release oxycodone.
DESIGN AND SETTING: Cross-sectional study in five U.S. methadone maintenance programs.
PARTICIPANTS: 92 addicts.
MEASUREMENTS: Self-reported questionnaire assessing past-month misuse of 14 opioid analgesics, and color photographs of five opioid analgesics with instructions to mark those used in the past month "to get high." Concordance between self-report and photograph endorsement was assessed via Kappa statistic.
FINDINGS: 29 respondents completed both questionnaire and photograph endorsements. Kappas were 0.62 (OxyContin), 0.59 (methadone), 0.49 (Dilaudid), and 0.46 (generic extended-release oxycodone).
CONCLUSIONS: Good-to-fair concurrent validity of self-reported abuse was seen for OxyContin, methadone, Dilaudid, and generic extended-release oxycodone.